January 4, 2019
KalGene Pharmaceuticals Inc., a biotechnology company developing therapeutics to slow the progression of Alzheimer's disease, today announced the appointment of James Callaway, Ph.D. as chief executive officer, effective immediately.
"This has been a very important transition year as we have confirmed our initial thesis with respect to validating the company's lead KG207, which in pre-clinical studies was shown to successfully cross the blood brain barrier and safely reduce plaque load. The company has successfully completed early toxicology studies and has carried out all the requisite steps to manufacture product," said Dr. Jacki Jenuth, Chairperson of the Kalgene's board of directors. "We are very pleased to have executed on the next key step of our strategy in attracting an accomplished new CEO to the company as we leverage this foundation and address significant inbound interest for the company and its lead program. Jim brings an ideal set of leadership skills and domain expertise to guide the team through the transition from a pre-clinical to a clinical stage company."
KalGene Pharmaceuticals Closes Financing to Support the Clinical Development of its Alzheimer's Therapeutic
November 27, 2017
KalGene Pharmaceuticals Inc. today announced the closing of a Series A financing to support the advancement of its lead Alzheimer's therapeutic program. The syndicated investment was led by Lumira Capital and included participation from Anges Québec, Anges Québec Capital, Accel-Rx Health Sciences Accelerator and a number of Canadian family offices. In addition to the equity financing the company has also received significant financial support from leading Foundations focused on neurodegenerative diseases. Proceeds from these combined funding sources will support the development of KalGene's lead Alzheimer's therapeutic candidate.
KalGene Pharmaceuticals Inc., NRC, CIMTEC and McGill to Present Ground-Breaking Preclinical Data During Alzheimer’s Disease Program at AAIC 2017
July 14, 2017
KalGene Pharmaceuticals Inc., in collaboration with the National Research Council of Canada (NRC), CIMTEC and the McGill Centre for Studies in Aging, have demonstrated that KalGene’s Alzheimer’s therapeutics candidate, licensed from the NRC (KAL-ABP-BBB), crosses the blood-brain barrier, and reduces amyloid-beta burden in a transgenic rat model after a four (4) week treatment. The results will be presented by McGill’s Dr. Pedro Rosa-Neto and the NRC’s Dr. Balu Chakravarthy at the Alzheimer’s Association International Conference (AAIC) in London in July 2017.
KalGene gears up to manufacture and test promising Alzheimer’s treatment with NRC, McGill and CIMTEC
October 3, 2016
KalGene Pharmaceuticals and the National Research Council of Canada (NRC) are proud to announce the signature of an agreement worth over $1M to develop, scale up, and transfer the technology needed to manufacture a promising novel Alzheimer’s treatment in Canada that the parties have been co- developing since 2015.
June 5, 2015
Canadian biotech KalGene Pharmaceuticals has successfully secured $1.5 million in financing from Brain Canada, CQDM, and the Ontario Brain Institute (OBI) Focus on Brain program to develop a new treatment for Alzheimer's. This funding from CQDM will allow KalGene to test the conjugated therapeutic in preclinical models and if successful, in patients.
National Research Council of Canada and KalGene Pharmaceuticals announce license agreement for the development of novel Alzheimer’s therapeutics
January 13, 2015
National Research Council of Canada (NRC) has granted KalGene Pharmaceuticals an exclusive worldwide license for a therapeutic molecule against Alzheimer’s disease.